Article
Treatment of patients with genotype 3 chronic hepatitis C--current and future therapies.
Liver international : official journal of the International Association for the Study of the Liver - 1 Feb 2012
Sarin Shiv K, Kumar Chandan K N
Abstract excerpt
Genotype 3 is a common type of HCV infection, and standard therapy using pegylated interferon (PEG-IFN) and ribavirin (RBV) is quite effective in these patients. While a short course of 16 weeks may result in comparable end of therapy responses, relapse rates are often high. A 24-week course is therefore preferable, and is expected to result in sustained virological response (SVR) rates of more than 70%. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.